Abbott Labs' (ABT) Libre Two Mobile App Cleared by FDA After a Year - Wells Fargo
Tweet Send to a Friend
Wells Fargo analyst Larry Biegelsen reiterated an Overweight rating and $135.00 price target on Abbott Labs (NYSE: ABT) noting that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
